SGLT-话题@MedSci

#SGLT#

125篇内容 | 3003人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1793791, encodeId=70481e9379195, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=Diabetes Obes Metab：2型糖尿病：不同SGLT2抑制剂的肾脏风险几何？, objectType=article, longId=111943, objectId=f4a3111943f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f4a3111943f6, replyNumber=0, likeNumber=91, createdTime=2018-06-13, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f4a3111943f6, moduleTitle=Diabetes Obes Metab：2型糖尿病：不同SGLT2抑制剂的肾脏风险几何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f4a3111943f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793797, encodeId=0a2d1e93797a8, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=JAHA：2型糖尿病患者SGLT2抑制剂的心血管安全和长期非心血管疗效分析！, objectType=article, longId=127162, objectId=547a12e162f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=547a12e162f7, replyNumber=0, likeNumber=97, createdTime=2018-05-03, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=547a12e162f7, moduleTitle=JAHA：2型糖尿病患者SGLT2抑制剂的心血管安全和长期非心血管疗效分析！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=547a12e162f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793787, encodeId=9bdf1e93787ef, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=Diabetes Obes Metab：2型糖尿病患者采用DPP-4is和SGLT-2is治疗疗效和安全性比较！, objectType=article, longId=103968, objectId=8f33103968a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f33103968a3, replyNumber=0, likeNumber=69, createdTime=2017-09-22, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f33103968a3, moduleTitle=Diabetes Obes Metab：2型糖尿病患者采用DPP-4is和SGLT-2is治疗疗效和安全性比较！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f33103968a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793788, encodeId=28c61e937883d, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=J Am Heart Assoc：SGLT2抑制剂对24小时动态血压有何影响？, objectType=article, longId=104953, objectId=af4f10495358, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=af4f10495358, replyNumber=0, likeNumber=66, createdTime=2018-06-23, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af4f10495358, moduleTitle=J Am Heart Assoc：SGLT2抑制剂对24小时动态血压有何影响？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=af4f10495358)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793792, encodeId=2e061e9379266, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=JCEM：餐后1小时高血糖或糖耐量异常者的十二指肠SGLT-1的表达增加, objectType=article, longId=114930, objectId=75b71149309d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=75b71149309d, replyNumber=0, likeNumber=67, createdTime=2018-08-05, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=75b71149309d, moduleTitle=JCEM：餐后1小时高血糖或糖耐量异常者的十二指肠SGLT-1的表达增加, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=75b71149309d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793785, encodeId=7ad71e937851c, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=NEJM: SGLT2抑制剂可增加糖尿病酮酸症的患病风险, objectType=article, longId=101327, objectId=111310132efa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=111310132efa, replyNumber=0, likeNumber=83, createdTime=2017-12-08, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=111310132efa, moduleTitle=NEJM: SGLT2抑制剂可增加糖尿病酮酸症的患病风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=111310132efa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793783, encodeId=66721e9378386, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=Circulation：SGLT-2抑制剂与其他降糖药对患者心脏衰竭和死亡风险的影响, objectType=article, longId=99260, objectId=9f869926077, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9f869926077, replyNumber=0, likeNumber=72, createdTime=2018-04-02, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9f869926077, moduleTitle=Circulation：SGLT-2抑制剂与其他降糖药对患者心脏衰竭和死亡风险的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9f869926077)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793784, encodeId=09f21e9378484, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=SCI REP：SGLT2抑制剂对2型糖尿病患者尿路感染和生殖系感染的影响！, objectType=article, longId=100925, objectId=35501009257d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=35501009257d, replyNumber=0, likeNumber=75, createdTime=2017-10-07, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=35501009257d, moduleTitle=SCI REP：SGLT2抑制剂对2型糖尿病患者尿路感染和生殖系感染的影响！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=35501009257d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793780, encodeId=5f9a1e937806e, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=FDA专家组12:11支持SGLT2抑制剂Jardiance标签扩展, objectType=article, longId=72020, objectId=e2b6e2020ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e2b6e2020ae, replyNumber=0, likeNumber=74, createdTime=2016-07-22, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e2b6e2020ae, moduleTitle=FDA专家组12:11支持SGLT2抑制剂Jardiance标签扩展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e2b6e2020ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793778, encodeId=47ad1e937781f, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=阿斯利康降糖药saxa/dapa（沙格列汀/达格列净）获欧盟CHMP支持批准，将成欧洲DPP-4i/SGLT-2i降糖药, objectType=article, longId=69403, objectId=04f76940319, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04f76940319, replyNumber=0, likeNumber=81, createdTime=2016-12-28, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04f76940319, moduleTitle=阿斯利康降糖药saxa/dapa（沙格列汀/达格列净）获欧盟CHMP支持批准，将成欧洲DPP-4i/SGLT-2i降糖药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=04f76940319)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793781, encodeId=e8591e93781c3, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=糖尿病患者福音！阿斯利康DPP4/SGLT2抑制剂组合疗法Qtern获欧盟批准, objectType=article, longId=73845, objectId=530de384583, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=530de384583, replyNumber=0, likeNumber=60, createdTime=2016-11-02, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=530de384583, moduleTitle=糖尿病患者福音！阿斯利康DPP4/SGLT2抑制剂组合疗法Qtern获欧盟批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=530de384583)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793777, encodeId=82141e937774c, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=Lancet Diabetes Endo：SGLT2抑制剂对2型糖尿病患者心血管健康的影响, objectType=article, longId=65071, objectId=efab650e1c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=efab650e1c7, replyNumber=0, likeNumber=105, createdTime=2016-10-20, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=efab650e1c7, moduleTitle=Lancet Diabetes Endo：SGLT2抑制剂对2型糖尿病患者心血管健康的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=efab650e1c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793774, encodeId=34eb1e9377484, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=CDS 2015：纪立农教授公布SGLT-2抑制剂心血管终点（Empa-REG OT 研究）, objectType=article, longId=60553, objectId=902360553c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=902360553c9, replyNumber=0, likeNumber=80, createdTime=2016-03-09, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=902360553c9, moduleTitle=CDS 2015：纪立农教授公布SGLT-2抑制剂心血管终点（Empa-REG OT 研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=902360553c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793779, encodeId=e7641e9377971, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=本周糖尿病重磅：强生降糖药INVOKAMET获FDA批准一线治疗2型糖尿病，英国NICE推荐3种SGLT-2降糖药, objectType=article, longId=69405, objectId=846b694053d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=846b694053d, replyNumber=0, likeNumber=109, createdTime=2016-06-25, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=846b694053d, moduleTitle=本周糖尿病重磅：强生降糖药INVOKAMET获FDA批准一线治疗2型糖尿病，英国NICE推荐3种SGLT-2降糖药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=846b694053d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793782, encodeId=ac421e93782d4, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=EASD 2016：阿斯利康2型糖尿病组合疗法Bydureon/Forxiga（GLP-1RA/SGLT-2i）III期临床显著降低血糖水平、体重、收缩压, objectType=article, longId=78308, objectId=7164e8308d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7164e8308d1, replyNumber=0, likeNumber=40, createdTime=2017-07-24, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7164e8308d1, moduleTitle=EASD 2016：阿斯利康2型糖尿病组合疗法Bydureon/Forxiga（GLP-1RA/SGLT-2i）III期临床显著降低血糖水平、体重、收缩压, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7164e8308d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793775, encodeId=bdb11e9377532, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=CDS 2015：洪天配解读DPP-4抑制剂与SGLT-2抑制剂在糖尿病治疗中的协同作用, objectType=article, longId=60556, objectId=f8216055671, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8216055671, replyNumber=0, likeNumber=77, createdTime=2016-01-10, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8216055671, moduleTitle=CDS 2015：洪天配解读DPP-4抑制剂与SGLT-2抑制剂在糖尿病治疗中的协同作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f8216055671)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793771, encodeId=bfa51e9377191, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=NEJM：SGLT2抑制剂恩格列净降糖同时心血管获益明显(EMPA-REG OUTCOME研究), objectType=article, longId=56883, objectId=6ed9568838d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ed9568838d, replyNumber=0, likeNumber=74, createdTime=2015-10-24, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ed9568838d, moduleTitle=NEJM：SGLT2抑制剂恩格列净降糖同时心血管获益明显(EMPA-REG OUTCOME研究), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6ed9568838d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793772, encodeId=2bf41e9377282, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=郭艺芳：SGLT-2抑制剂——具有降糖作用的降压药, objectType=article, longId=60091, objectId=38b0600912e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=38b0600912e, replyNumber=0, likeNumber=89, createdTime=2015-12-20, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=38b0600912e, moduleTitle=郭艺芳：SGLT-2抑制剂——具有降糖作用的降压药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=38b0600912e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793776, encodeId=416b1e9377693, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=CDS 2015：MedSci专访纪立农教授：SGLT2抑制剂恩格列净降糖同时心血管获益明显, objectType=article, longId=60612, objectId=545f6061209, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=545f6061209, replyNumber=0, likeNumber=78, createdTime=2016-04-10, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=545f6061209, moduleTitle=CDS 2015：MedSci专访纪立农教授：SGLT2抑制剂恩格列净降糖同时心血管获益明显, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=545f6061209)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793773, encodeId=2a561e9377328, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, objectTitle=FDA警告：糖尿病治疗新秀“SGLT2抑制剂”导致酮症酸中毒风险, objectType=article, longId=60331, objectId=8b316033177, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8b316033177, replyNumber=0, likeNumber=100, createdTime=2016-04-26, rootId=0, userName=tulenzi, userId=54f9127, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8b316033177, moduleTitle=FDA警告：糖尿病治疗新秀“SGLT2抑制剂”导致酮症酸中毒风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8b316033177)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

SGLT

2020-05-29

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

Diabetes Obes Metab：2型糖尿病：不同SGLT2抑制剂的肾脏风险几何？

2018-06-13

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

JAHA：2型糖尿病患者SGLT2抑制剂的心血管安全和长期非心血管疗效分析！

2018-05-03

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

Diabetes Obes Metab：2型糖尿病患者采用DPP-4is和SGLT-2is治疗疗效和安全性比较！

2017-09-22

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

J Am Heart Assoc：SGLT2抑制剂对24小时动态血压有何影响？

2018-06-23

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

JCEM：餐后1小时高血糖或糖耐量异常者的十二指肠SGLT-1的表达增加

2018-08-05

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

NEJM: SGLT2抑制剂可增加糖尿病酮酸症的患病风险

2017-12-08

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

Circulation：SGLT-2抑制剂与其他降糖药对患者心脏衰竭和死亡风险的影响

2018-04-02

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

SCI REP：SGLT2抑制剂对2型糖尿病患者尿路感染和生殖系感染的影响！

2017-10-07

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

FDA专家组12:11支持SGLT2抑制剂Jardiance标签扩展

2016-07-22

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

阿斯利康降糖药saxa/dapa（沙格列汀/达格列净）获欧盟CHMP支持批准，将成欧洲DPP-4i/SGLT-2i降糖药

2016-12-28

仁者大医 (审核中...)

前往app查看评论内容

#SGLT#

糖尿病患者福音！阿斯利康DPP4/SGLT2抑制剂组合疗法Qtern获欧盟批准

2016-11-02

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

Lancet Diabetes Endo：SGLT2抑制剂对2型糖尿病患者心血管健康的影响

2016-10-20

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

CDS 2015：纪立农教授公布SGLT-2抑制剂心血管终点（Empa-REG OT 研究）

2016-03-09

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

本周糖尿病重磅：强生降糖药INVOKAMET获FDA批准一线治疗2型糖尿病，英国NICE推荐3种SGLT-2降糖药

2016-06-25

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

EASD 2016：阿斯利康2型糖尿病组合疗法Bydureon/Forxiga（GLP-1RA/SGLT-2i）III期临床显著降低血糖水平、体重、收缩压

2017-07-24

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

CDS 2015：洪天配解读DPP-4抑制剂与SGLT-2抑制剂在糖尿病治疗中的协同作用

2016-01-10

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

NEJM：SGLT2抑制剂恩格列净降糖同时心血管获益明显(EMPA-REG OUTCOME研究)

2015-10-24

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

郭艺芳：SGLT-2抑制剂——具有降糖作用的降压药

2015-12-20

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

CDS 2015：MedSci专访纪立农教授：SGLT2抑制剂恩格列净降糖同时心血管获益明显

2016-04-10

tulenzi (审核中...)

前往app查看评论内容

#SGLT#

FDA警告：糖尿病治疗新秀“SGLT2抑制剂”导致酮症酸中毒风险

2016-04-26

科室
- - 订阅+
  - 更多科室
工具
服务